{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-108422","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.416910+00:00","generated_at":"2026-05-17T13:11:20.693654+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Palvella Q2 net loss $9.5M; Phase 3 LM trial enrollment exceeded target by 25%","bullets":["Phase 3 SELVA enrolled 51 subjects (target 40); top-line results expected Q1 2026.","Cash $70.4M; expected to fund operations into second half of 2027.","Net loss $9.5M ($0.86/share) vs $4.4M ($2.47); R&D and G&A up due to trial costs.","Company plans to announce third QTORIN rapamycin indication and second platform candidate before year-end 2025.","Appointed Ashley Kline as Chief Commercial Officer; added to Russell 2000/3000 indexes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-108422","json":"https://secwatch.observer/filing/0000950170-25-108422.json","markdown":"https://secwatch.observer/filing/0000950170-25-108422.md","text":"https://secwatch.observer/filing/0000950170-25-108422.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000095017025108422/0000950170-25-108422-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000095017025108422/pvla-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:11:20.693654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}